FUNDUSCEIN-25
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUNDUSCEIN-25 is a small-molecule injectable diagnostic agent approved in 1976 by Novartis. The specific indication and mechanism of action are not publicly documented in available data; however, the name suggests fluorescein-based ophthalmic diagnostic use. This product represents a legacy therapeutic with established clinical utility in its indication.
LOE Approaching
With LOE approaching and minimal linked job activity, this mature product likely operates with a small, stable team focused on maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal hiring activity on this product. Working on FUNDUSCEIN-25 offers stability in a legacy diagnostic franchise but limited growth potential or career acceleration.
Product ManagerField Sales Representative
Worked on FUNDUSCEIN-25 at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.